Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.04%
#2 Ocean Protocol Ocean Protocol +21.09%
#3 KUB Coin KUB Coin +16.96%
#4 Geodnet Geodnet +13.74%
#5 Audiera Audiera +12.11%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +8.18%
#7 Arowana Arowana +7.88%
#8 DexNet DexNet +7.78%
#9 Cysic Cysic +7.51%
#10 Ontology Gas Ontology Gas +6.91%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Innstillinger
Språk
NORSK
Valuta
USD
Tema
RIV Capital Inc. RIV Capital Inc.

RIV Capital Inc.

RIV
Rangering i aksjer #32450
RIV Capital Inc., formerly known as Canopy Rivers Inc., operates as a venture... RIV Capital Inc., formerly known as Canopy Rivers Inc., operates as a venture capital firm with a versatile investment approach. While open to opportunities across all company stages, from initial seed funding through commercialization, its primary focus is on Series A through C financing rounds. The firm's strategic interest is firmly rooted in the burgeoning cannabis sector, actively seeking out promising marijuana-related businesses and adjacent industries. Its comprehensive investment scope encompasses a wide array of areas: Agriculture and food sciences: Spanning plant, soil, food, animal, and environmental science. Production: Including diverse cultivation methods such as indoor, greenhouse, outdoor, and nursery, alongside fermentation. Processing: Involving harvesting, extraction, purification, packaging, food and beverage processing, and laboratory testing services. Pharmaceuticals and biotechnology: Covering drug discovery and development, various delivery methods (e.g., pills, soft gels, tinctures), biosynthetic derived cannabinoids, medical devices (e.g., inhalers), and lab equipment. Technology and consumer goods: Such as software and data, specialized hardware, consumer products and accessories (e.g., edibles, beverages, inhalables, cosmetics, cannabis consumption tools), and wellness products. Market access: Including retail and distribution channels (licensed brick-and-mortar stores, pharmacies, online marketplaces, delivery services), and media and content creation. Furthermore, specific product categories of interest include beverages, capsules, concentrates, edibles, dry flower/pre-rolls, vaporizers and associated hardware, pet products, and topicals. RIV Capital actively pursues investment prospects on a global scale. While check sizes have historically ranged from CA$1 million (approximately $0.71 million USD) to CA$40 million (around $28.45 million USD), the firm typically invests between CA$5 million (roughly $3.6 million USD) and CA$10 million (approximately $7.1 million USD). The firm generally seeks to acquire minority ownership stakes and employs a flexible array of investment instruments, including debt financing, preferred and common equity, and production-linked royalties. RIV Capital Inc. was established in 2017 and is headquartered in Toronto, Canada.
Aksjekurs
$0.07339369
Sist synkronisert: 2024-12-19
Markedsverdi
$10.05M
Endring (1 dag)
0.98%
Endring (1 år)
0.00%
Land
CA
Handel RIV Capital Inc. (RIV)

Kategori

Healthcare
P/E-forhold for RIV Capital Inc. (RIV)
P/E-forhold per 2026 TTM: 0
Ifølge RIV Capital Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for RIV Capital Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 38.29 -
IN
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.